INCHEON, South Korea, December 18, 2025--(BUSINESS WIRE)--Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has ...
Biosimilar partnerships and EU approvals surge, enhancing access to innovative treatments in immunology, oncology, and bone ...
STEQEYMA is indicated for the treatment of plaque psoriasis (PsO) and psoriatic arthritis (PsA) in adult and pediatric patients, as well as Crohn's disease (CD) and ulcerative colitis (UC) in adult ...
SEOUL, Oct. 15 (Yonhap) -- South Korean biopharmaceutical company Celltrion Inc. said Wednesday its biosimilar for autoimmune diseases has received regulatory approval for sale in New Zealand. The New ...
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback